These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38797152)

  • 1. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice.
    Wang B; Zhu X; Yu S; Xue H; Deng L; Zhang Y; Zhang Y; Liu Y
    Biochem Biophys Res Commun; 2024 Aug; 722():150170. PubMed ID: 38797152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
    Tao X; He H; Peng J; Xu R; Fu J; Hu Y; Li L; Yang X; Feng X; Zhang C; Zhang L; Yu X; Shen A; Huang K; Fu Q
    Pharmacol Res; 2022 Jan; 175():106004. PubMed ID: 34826603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways.
    Essam RM; Ahmed LA; Abdelsalam RM; El-Khatib AS
    Life Sci; 2019 Apr; 222():245-254. PubMed ID: 30858122
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Kim HJ; Jeon HJ; Kim DG; Kim JY; Shim JJ; Lee JH
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvianolic acid B ameliorates non-alcoholic fatty liver disease by inhibiting hepatic lipid accumulation and NLRP3 inflammasome in ob/ob mice.
    Meng LC; Zheng JY; Qiu YH; Zheng L; Zheng JY; Liu YQ; Miao XL; Lu XY
    Int Immunopharmacol; 2022 Oct; 111():109099. PubMed ID: 35932615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PDE5 inhibitor udenafil ameliorates nonalcoholic fatty liver disease by improving mitochondrial function.
    Yu HM; Chung HK; Park KS
    Biochem Biophys Res Commun; 2021 Jun; 558():57-63. PubMed ID: 33895552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism.
    Möllmann J; Kahles F; Lebherz C; Kappel B; Baeck C; Tacke F; Werner C; Federici M; Marx N; Lehrke M
    Diabetes Obes Metab; 2017 Apr; 19(4):496-508. PubMed ID: 27917591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease.
    Wilson RB; Chen YJ; Sutherland BG; Sawyez CG; Zhang R; Woolnough T; Hetherington AM; Peters KM; Patel K; Kennelly JP; Leonard KA; Schuurman M; Jacobs RL; Wang R; Borradaile NM
    Pharmacol Res; 2020 Nov; 161():105208. PubMed ID: 32977024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
    Wang Z; Li S; Wang R; Guo L; Xu D; Zhang T; Xu Y; Wang W; Wang M; Gan Z; Wang X
    Mol Med; 2020 Jun; 26(1):54. PubMed ID: 32503411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non‑alcoholic fatty liver disease mouse model.
    Lu Y; Lin Y; Huang X; Wu S; Wei J; Yang C
    Int J Mol Med; 2019 Jun; 43(6):2398-2408. PubMed ID: 30942432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1.
    Jian T; Yu C; Ding X; Chen J; Li J; Zuo Y; Ren B; Lv H; Li W
    J Oleo Sci; 2019 Jun; 68(6):581-589. PubMed ID: 31092797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic effects of resveratrol on hepatic steatosis in high-fat diet-induced obese mice by improving oxidative stress, inflammation and lipid-related gene transcriptional expression.
    Cheng K; Song Z; Zhang H; Li S; Wang C; Zhang L; Wang T
    Med Mol Morphol; 2019 Dec; 52(4):187-197. PubMed ID: 30673851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hesperetin ameliorates hepatic oxidative stress and inflammation
    Li J; Wang T; Liu P; Yang F; Wang X; Zheng W; Sun W
    Food Funct; 2021 May; 12(9):3898-3918. PubMed ID: 33977953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.
    Ding H; Li N; He X; Liu B; Dong L; Liu Y
    Int Urol Nephrol; 2017 Oct; 49(10):1723-1730. PubMed ID: 28756610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supplementation with a Specific Combination of Metabolic Cofactors Ameliorates Non-Alcoholic Fatty Liver Disease, Hepatic Fibrosis, and Insulin Resistance in Mice.
    Quesada-Vázquez S; Colom-Pellicer M; Navarro-Masip È; Aragonès G; Del Bas JM; Caimari A; Escoté X
    Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease.
    Li DJ; Liu J; Hua X; Fu H; Huang F; Fei YB; Lu WJ; Shen FM; Wang P
    Metabolism; 2018 Feb; 79():52-63. PubMed ID: 29129819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.